Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan

详细信息    查看全文

• 作者：Remington L Nevin (1)
  Paul P Pietrusiak (2)
  Jennifer B Caci (3)
  
• 刊名：Malaria Journal
• 出版年：2008
• 出版时间：December 2008
• 年：2008
• 卷：7
• 期：1
• 全文大小：471KB
• 参考文献：1. Ciminera P, Brundage J: Malaria in US military forces: a description of deployment exposures from 2003 through 2006. / Am J Trop Med Hyg 2007, 76: 275鈥?79.
  2. Kotwal RS, Wenzel RB, Sterling RA, Porter WD, Jordan NN, Petrucelli BP: An outbreak of malaria in US Army Rangers returning from Afghanistan. / JAMA 2007, 293 (2) : 212鈥?16. CrossRef
  3. Chen LH, Wilson ME, Schlagenhauf P: Prevention of malaria in long-term travelers. / JAMA 2007, 296 (18) : 2234鈥?244. CrossRef
  4. Chen LH, Wilson ME, Schlagenhauf P: Controversies and misconceptions in malaria chemoprophylaxis for travelers. / JAMA 2007, 297: 2251鈥?263. CrossRef
  5. Wells TS, Smith TC, Smith B, Wang LZ, Hansen CJ, Reed RJ, Goldfinger WE, Corbeil TE, Spooner CN, Ryan MAK: Mefloquine use and hospitalizations among US service members, 2002鈥?004. / Am J Trop Med Hyg 2006, 74: 744鈥?49.
  6. Roche Laboratories Inc: / Lariam庐 (mefloquine hydrochloride) Complete Product Information Nutley, NJ 2004.
  7. Rubertone MV, Brundage JF: The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. / Am J Public Health 2002, 92: 1900鈥?904. CrossRef
  8. Pavlin JA, Murdock P, Elbert E, Milliken C, Hakre S, Mansfield J, Hoge C: Conducting population behavioral health surveillance by using automated diagnostic and pharmacy data systems. / MMWR 2004, (Suppl 53) : 166鈥?72.
  9. U.S. Department of Health and Human Services: / International Classification of Diseases 9th Revision Clinical Modification US Government Printing Office 1980.
  10. SAS Institute: / SAS/STAT庐 9.1 Users Guide SAS Institute 2004.
  11. Haley RW: Point: bias from the "healthy-warrior effect" and unequal follow-up in three government studies of health effects of the Gulf War. / Am J Epidemiol 1998, 148: 315鈥?3.
  12. Seal KH, Bertenthal D, Miner CR, Sen S, Marmar C: Bringing the war back home: mental health disorders among 103,788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs facilities. / Arch Intern Med 2007, 167: 476鈥?2. CrossRef
  13. Hoge CW, Auchterlonie JL, Milliken CS: Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan. / JAMA 2006, 295: 1023鈥?2. CrossRef
  14. Hill DR: Pre-travel health, immunization status, and demographics of travel to the developing world for individuals visiting a travel medicine service. / Am J Trop Med Hyg 1991, 45: 263鈥?70.
  15. Crockett M, Kain KC: Tafenoquine: a promising new antimalarial agent. / Expert Opin Investig Drugs 2007, 16: 705鈥?5. CrossRef
  16. Kitchener S, Nasveld P, Edstein MD: Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. / Am J Trop Med Hyg 2007, 76: 494鈥?.
  17. Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duelm F, Hospenthal DR: Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. / Mil Med 2006, 171: 905鈥?.
  
• 作者单位：Remington L Nevin (1)
  Paul P Pietrusiak (2)
  Jennifer B Caci (3)
  
  1. Army Medical Surveillance Activity, 2900 Linden Lane, Suite 200, 20910, Silver Spring, MD, USA
  2. US Army Center for Health Promotion and Preventive Medicine, APG, 21010, MD, USA
  3. Headquarters, 82nd Airborne Division, Ft. Bragg, 28310, NC, USA
  

文摘

Background Mefloquine has historically been considered safe and well-tolerated for long-term malaria chemoprophylaxis, but its prescribing requires careful attention to rule out contraindications to its use, including a history of certain psychiatric and neurological disorders. The prevalence of these disorders has not been defined in cohorts of U.S. military personnel deployed to areas where long-term malaria chemoprophylaxis is indicated. Methods Military medical surveillance and pharmacosurveillance databases were utilized to identify contraindications to mefloquine use among a cohort of 11,725 active duty U.S. military personnel recently deployed to Afghanistan. Results A total of 9.6% of the cohort had evidence of a contraindication. Females were more than twice as likely as males to have a contraindication (OR = 2.48, P < 0.001). Conclusion These findings underscore the importance of proper systematic screening prior to prescribing and dispensing mefloquine, and the need to provide alternatives to mefloquine suitable for long-term administration among deployed U.S. military personnel.